INTERVENTIONAL CARDIOLOGY AND SURGERY

In-hospital time to treatment of patients with acute ST elevation myocardial infarction treated with primary angioplasty: determinants and outcome. Results from the registry of percutaneous coronary interventions in acute myocardial infarction of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte

R Zahn, A Vogt, U Zeymer, A K Gitt, K Seidl, M Gottwik, M A Weber, W Niederer, B Mödl, H-J Engel, U Tebbe, J Senges, for the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte

Heart 2005;91:1041-1046. doi: 10.1136/hrt.2004.045336

Objective: To determine the predictors of time between presentation and primary angioplasty and the influence of this delay time on in-hospital mortality in clinical practice.

Design: Analysis of data from the registry of percutaneous coronary interventions in acute myocardial infarction of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK).

Patients: Data of 4815 patients registered at 80 hospitals between 1994 and 2000 were analysed.

Results: Mean age of the patients was 61.4 (12.5) years. Cardiogenic shock was present in 14.1%. Mean time from admission to primary angioplasty ("door to angiography" time) was 83 (122) minutes. Logistic regression analysis showed the presence of a bundle branch block (odds ratio (OR) 1.95, 95% confidence interval (CI) 1.15 to 3.29), prior coronary artery bypass grafting (OR 1.67, 95% CI 1.08 to 2.59), pre-hospital delay > 3 hours (OR 1.61, 95% CI 1.37 to 1.89), and female sex (OR 1.21, 95% CI 1.01 to 1.45) to be independently associated with longer door to angiography times, whereas a higher hospital volume of performing primary angioplasty (OR 0.53, 95% CI 0.46 to 0.62) and the year of the investigation (OR 0.96, 95% CI 0.92 to 1.00) were independently associated with shorter door to angiography times. Independent predictors of in-hospital mortality were cardiogenic shock (41.6% v 4.0% without cardiogenic shock, $p < 0.0001$), technical success (29.2% with TIMI (thrombolysis in myocardial infarction) flow < 3 v 6.5% with TIMI flow 3, $p < 0.0001$), age (16.5% $\geq$ 70 years v 6.6% < 70, $p < 0.0001$), three vessel disease (16.5% v 6.8% with < 3 vessel disease, $p < 0.0001$), anterior location of infarction (12% v 7.4% without anterior infarction, $p < 0.0001$), year of inclusion (adjusted OR 0.92 per year, $p = 0.011$), and volume of primary angioplasty at the hospital (11% for < 20 angioplasty procedures/year v 8.3% for $\geq$ 20/year, $p = 0.027$) but not the door to angiography time (adjusted OR 1.14 per tertile, $p = 0.397$).

Conclusions: In current clinical practice in Germany median door to angiography time is quite short (83 (122) minutes). Some patients and hospital factors are independently associated with a longer door to angiography time. Within the observed short in-hospital delays door to angiography time did not influence in-hospital mortality. However, efforts to keep them as short as possible should be continued.

See end of article for authors' affiliations

Correspondence to: Dr Ralf Zahn, Herzzentrum Ludwigshafen, Department of Cardiology, Bremsersstraße 79, D-67063 Ludwigshafen, Germany; erzahn@aol.com

11 October 2004

In patients with acute ST elevation myocardial infarction (STEMI) reperfusion with primary angioplasty is superior to intravenous thrombolysis regarding in-hospital mortality, repeat infarctions, strokes, and cerebral bleeding.^{1 2} This difference becomes more pronounced with increasing time from symptom onset to start of reperfusion.³⁻⁵

For thrombolysis a clear relation between mortality and time delay between symptom onset and the initiation of thrombolysis has been shown.⁶⁻⁸ In contrast, data concerning the influence of time to treatment with primary angioplasty are conflicting. Most studies have suggested that treatment with primary angioplasty may not be as time dependent as treatment with thrombolysis.^{3 5 9-12} This difference between primary angioplasty and thrombolysis may result from differences in the time dependent effect on achieving TIMI (thrombolysis in myocardial infarction) grade 3 flow.¹³ In the case of primary angioplasty there seems to be no major effect

of time to treatment on the rate of TIMI grade 3 flow.^{11 12} However, in the case of thrombolysis, longer times to treatment are associated with lower patency rates. This is more pronounced for streptokinase¹⁴ and for urokinase¹⁵ than for tissue plasminogen activator, but tissue plasminogen activator also becomes less effective with longer times to treatment.¹⁵

An analysis of the NRMI-2 (second national registry of myocardial infarction) data showed, however, that if the treating physician or hospital delays the start of primary angioplasty while the patient is already in the hospital, which

Abbreviations: ALKK, Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte; AML, acute myocardial infarction; CI, confidence interval; NRMI-2, second national registry of myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention; STEMI, ST elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction

is the case with long times from hospital admission until the beginning of primary angioplasty ("door to angiography" time), then longer delays are associated with increasing mortality.¹⁰ In contrast a recent analysis of the Zwolle database did not confirm these findings.¹⁶

To investigate the predictors of door to angiography times and their influence on primary angioplasty on in-hospital mortality in clinical practice, we analysed data from the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) registry of percutaneous coronary interventions (PCI) in acute myocardial infarction (AMI).

METHODS

The ALKK registry of PCI in AMI

The PCI registry of the ALKK contains all PCI procedures from 80 centres in Germany since October 1992. Details of the organisation of the registry have been published previously.¹⁷ In brief, all interventions were prospectively registered by telephone or fax to the coordinating centre in Kassel, Germany. All complications occurring in the catheter room and during the hospital stay were prospectively documented.

From July 1994 until the end of 2000 a subregistry was opened of all PCI procedures in AMI within 24 hours after symptom onset in more detail than in the general registry.¹⁸ Only the procedures from this subregistry were analysed for this report. All data were collected prospectively and analysed centrally.

Definitions

STEMI was diagnosed in the presence of the two following criteria: persistent angina pectoris for ≥ 20 minutes and ST segment elevation of ≥ 1 mm in at least two standard leads or ≥ 2 mm in at least two contiguous precordial leads or the presence of a left bundle branch block. It was later confirmed by the increase of cardiac enzymes of > 3 times the normal upper range. Pre-hospital delay was defined as the time from the onset of symptoms until hospital admission. In-hospital delay (door to angiography time) was defined as the time from admission to the hospital until the start of primary angioplasty (angiographic needle entry). Angioplasty was performed according to the standard protocol of each centre. The physician performing the intervention evaluated the success of primary angioplasty according to the TIMI flow grade.¹³

Patient selection

All patients undergoing PCI for STEMI within 12 hours after symptom onset were considered for this analysis. Patients were excluded from this analysis if pre-hospital delay was longer than 12 hours, if patients were treated with thrombolysis before PCI, if patients had a non-STEMI, or if patients were transferred from other hospitals for primary angioplasty (fig 1). Transferred patients were not included because recording of time intervals started with the patient's admission at the PCI centre and not at the primary hospital.

Statistical analysis

Absolute numbers, percentages, and mean (SD) were computed to describe the patient population. Categorical values were compared by χ^2 analysis. Continuous variables were compared by analysis of variance. Door to angiography times were divided into tertiles to investigate angiographic success and in-hospital mortality according to the door to angiography time. Multiple logistic regression analysis was used to adjust for factors influencing door to angiography times and in-hospital mortality. The following variables were examined in the model of door to angiography times: age, sex, location of infarction, cardiogenic shock, previous

* in transfer patients, time intervals were not evaluated in detail to differentiate between the initial hospital and the interventional hospital. Therefore those patients had to be excluded from the current analysis.

Figure 1 Selection of patients from the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) registry of percutaneous coronary interventions in acute myocardial infarction (AMI). BBB, bundle branch block; PTCA, percutaneous transluminal coronary angioplasty.

coronary bypass surgery, presence of a bundle branch block, pre-hospital delay, volume of primary angioplasty at each hospital, and the year of inclusion. The following variables were examined in the model of in-hospital mortality: age, sex, location of infarction, cardiogenic shock, previous coronary bypass surgery, presence of a bundle branch block, volume of primary angioplasty at each hospital, year of inclusion, technical success (TIMI 3 flow after primary angioplasty), and tertiles of the door to angiography time. Pre-hospital delay was not included in this model because it was not associated with mortality in univariate analysis. Further logistic regression analyses regarding mortality were done separately for patients with and without cardiogenic shock and after exclusion of technical success from the model. We also compared the mortality rates of patients with a door to angiography time < 120 minutes with those ≥ 120 minutes. All p values are results of two tailed tests. All statistical calculations were made with the CSS STATISTICA software package from StatSoft, Inc (Tulsa, Oklahoma, USA).

Figure 2 Distribution of door to angiography times.

RESULTS

Patients

Between July 1994 and the end of 2000 a total of 10 946 patients from 80 hospitals were entered into the ALKK PCI in AMI registry. Of these patients, 4815 with STEMI were admitted within 12 hours after onset of symptoms primarily to a hospital with PCI facilities and did not receive thrombolysis before angioplasty (fig 1).

Door to angiography times

Figure 2 shows the distribution of the door to angiography times. Mean (SD) door to angiography time was 83 (122) minutes. In most patients PCI was started within 60 minutes after admission to the hospital and only a few patients had a door to angiography time exceeding 120 minutes.

Mean (SD) age of the patients was 61.4 (12.5) years and 25.6% of patients were women (table 1). Cardiogenic shock was present in 14.1%. With increasing in-hospital delay, age increased slightly ($p = 0.002$) as did the proportion of women ($p = 0.025$). With longer door to angiography time pre-hospital delays also increased, from 166 (152) minutes (first tertile) to 204 (173) minutes (last tertile, $p < 0.0001$).

Logistic regression analysis showed the presence of a bundle branch block (odds ratio (OR) 1.95, 95% confidence interval (CI) 1.15 to 3.29), prior coronary artery bypass grafting (OR 1.67, 95% CI 1.08 to 2.59), a pre-hospital delay > 3 hours (OR 1.61, 95% CI 1.37 to 1.89), and female sex (OR 1.21, 95% CI 1.01 to 1.45) to be independently associated with longer door to angiography times, whereas a higher hospital volume of performing primary angioplasty (OR 0.53, 95% CI 0.46 to 0.62) and a more recent year of investigation (OR 0.96, 95% CI 0.92 to 1.00) were independently associated with shorter door to angiography times (table 2).

Angiographic success and in-hospital mortality

TIMI grade 3 flow was achieved in 87.5% of all patients. Among patients with door to angiography times < 30 minutes, 89.3% had TIMI grade 3 flow, among patients with door to angiography times between 31–60 minutes 89.0% had TIMI grade 3 flow, and among patients with door to angiography times > 60 minutes 84.1% achieved TIMI grade 3 flow ($p = 0.0005$). In-hospital mortality was 9.2% with door to angiography times < 30 minutes, 8.3% with door to angiography times between 30–60 minutes, and 10.5% in patients with door to angiography times > 60 minutes ($p = 0.552$; table 1).

Independent predictors of in-hospital mortality were cardiogenic shock ($p < 0.0001$), technical success ($p < 0.0001$), age ($p < 0.0001$), three vessel disease ($p < 0.0001$), location of infarction ($p < 0.0001$), year of inclusion ($p = 0.011$), and volume of primary angioplasty in each hospital ($p = 0.027$) but not the door to angiography times ($p = 0.397$) (table 3). These data did not change substantially if the technical success rate was excluded from the regression model. In-hospital mortality was not significantly lower among patients who started treatment within 30 minutes after admission than among patients treated within 31–60 minutes (OR 1.02, 95% CI 0.49 to 2.13) or later than 60 minutes (OR 1.16, 95% CI 0.74 to 1.84) (fig 3). These data did not change if patients presenting with and without cardiogenic shock were analysed separately.

In-hospital mortality was 12.2% in patients with door to angiography times ≥ 120 minutes compared with 8.8% in patients with door to angiography times < 120 minutes ($p = 0.118$, after adjustment for confounding parameters: OR 1.34, 95% CI 0.97 to 1.85, $p = 0.098$).

DISCUSSION

The data of the ALKK PCI in AMI registry obtained in 80 hospitals in Germany showed a mean door to angiography time of 83 (122) minutes, with only a few patients having a delay exceeding 120 minutes. The presence of a bundle branch block, prior coronary artery bypass grafting, a pre-hospital delay > 3 hours, and female sex were independently associated with longer door to angiography times, whereas a higher hospital volume of performing primary angioplasty (OR 0.53, 95% CI 0.46 to 0.62) and a more recent year of inclusion (OR 0.96, 95% CI 0.92 to 1.00) were independently associated with a shorter door to angiography time. Under these circumstances of short in-hospital delays, we found no influence of the door to angiography time on in-hospital mortality.

Door to angiography times in the ALKK PCI in AMI registry

The observed 50 minute median (quartiles of 31–75 minutes) door to angiography time in our analysis of the ALKK PCI in AMI registry is much shorter than the 116 minute median (quartiles of 95–163 minutes) of the NRM-2, in which only 8% of patients had a door to balloon time of 60 minutes or less.¹⁰ Although obtained at 80 hospitals in Germany these data are very close to the data from the single centre registry

Table 1 Baseline characteristics and outcome by door to angiography time

	Time (min)				p Value
	Overall	0–30	31–60	>60	
Number of patients	4815	1487	1777	1551	
Age (years)	61.4 (12.5)	61.0 (12.2)	60.8 (12.4)	62.3 (12.9)	0.002
Women	25.6%	23.5%	24.1%	29.5%	0.025
Prior PTCA	8.7%	8.5%	9.2%	8.3%	0.261
Prior CABG	2.5%	2.6%	1.9%	3.0%	0.675
Anterior wall MI	42.1%	42.4%	40.9%	43.1%	0.933
Bundle branch block	1.5%	0.94%	1.7%	1.9%	0.497
Cardiogenic shock	14.1%	16.3%	12.9%	13.2%	0.166
Pre-hospital delay (min)	180 (158)	166 (152)	169 (145)	204 (173)	<0.0001
Three vessel disease	24.4%	23.3%	21.8%	28.6%	0.0001
TIMI 3 flow after primary angioplasty	87.5%	89.3%	89.0%	84.1%	0.0005
In-hospital mortality	9.3%	9.2%	8.3%	10.5%	0.552
OR	NA	1 (reference)	0.89	1.16	NA
95% CI	NA		0.70 to 1.13	0.91 to 1.47	
p Value	NA	NA	0.375	0.256	NA

CABG, coronary artery bypass grafting; CI, confidence interval; MI, myocardial infarction; NA, not applicable; OR, odds ratio; PTCA, percutaneous transluminal coronary angioplasty; TIMI, thrombolysis in myocardial infarction.

Table 2 Predictors of door to angiography time >90 minutes

Parameter	Time >90 minutes	p Value	Adjusted OR	95% CI	p Value
Age ≥70 years	20.0%	0.183	1.16	0.97 to 1.38	0.101
Age <70 years	16.9%				
Female sex	20.1%	0.302	1.21	1.01 to 1.45	0.032
Male sex	16.9%				
BBB	29.7%	0.114	1.95	1.15 to 3.29	0.012
No BBB	17.5%				
Anterior STEMI	17.4%	0.996	0.97	0.82 to 1.13	0.689
No anterior STEMI	17.9%				
Cardiogenic shock	16.1%	0.835	0.85	0.67 to 1.08	0.179
No cardiogenic shock	18.0%				
Prior CABG	27.7%	0.078	1.67	1.08 to 2.59	0.022
No prior CABG	17.5%				
Pre-hospital delay					
>3 hours	23.1%	<0.0001	1.61	1.37 to 1.89	<0.0001
0–3 hours	15.1%				
Volume of primary PTCA					
≥20/year	14.3%	<0.0001	0.53	0.46 to 0.62	<0.0001
<20/year	23.5%				
Year of intervention					
1994	16.4%	0.845	0.96 (per year)	0.92 to 1.00	0.037
1995	18.6%				
1996	18.8%				
1997	19.8%				
1998	17.7%				
1999	15.2%				
2000	18.9%				

BBB, bundle branch block; STEMI, ST elevation myocardial infarction.

in Zwolle (mean 55 (36) minutes door to balloon time).¹⁶ Door to angiography time is not door to balloon time, but this difference is usually 10–15 minutes in clinical practice and therefore does not explain the observed large differences in time between the ALKK and the NRMI-2 studies. Door to angiography time may be the more objective way to look at

time intervals because it is similar to an intention to treat way to handle primary angioplasty. This becomes obvious in the small group of patients in whom reperfusion cannot be achieved because the obstructed vessel cannot be crossed by a guidewire. No balloon can be used in such circumstances and these patients have a high mortality.¹⁸ How such patients

Table 3 Predictors of in-hospital mortality

Parameter	In-hospital mortality	p Value	Adjusted OR	95% CI	p Value
Cardiogenic shock	41.6%	<0.0001	16.56	12.9 to 21.2	<0.0001
No cardiogenic shock	4.0%				
Technical success					
Final TIMI flow <3	29.2%	<0.0001	4.89	3.73 to 6.41	<0.0001
Final TIMI flow 3	6.5%				
Age ≥70 years	16.5%	<0.0001	2.59	2.00 to 3.34	<0.0001
Age <70 years	6.6%				
3 Vessel disease	16.5%	<0.0001	1.97	1.53 to 2.53	<0.0001
<3 Vessel disease	6.8%				
BBB	33.8%	<0.0001	1.81	0.92 to 3.56	0.086
No BBB	8.9%				
Anterior STEMI	12.0%	<0.0001	1.80	1.41 to 2.29	<0.0001
No anterior STEMI	7.4%				
Year of intervention					
1994	10.7%	0.108	0.92 (per year)	0.87 to 0.98	0.011
1995	11.2%				
1996	9.9%				
1997	8.3%				
1998	9.6%				
1999	9.4%				
2000	8.3%				
Volume of primary PTCA					
≥20/year	8.3%	0.037	0.76	0.59 to 0.97	0.027
<20/year	11.0%				
Pre-hospital delay*					
>3 hours	9.03	0.99	NA	NA	NA
0–3 hours	9.35				
Door to angiography time					
≤30 minutes	9.2%	0.552	1.14 (per tertile)	0.84 to 1.53	0.313
31–60 minutes	8.3%				
>60 minutes	10.5%				

*Not included in the logistic regression model.

Figure 3 Relation between door to angiography time intervals and mortality. CI, confidence interval; OR, odds ratio.

were handled in the Zwolle registry is not mentioned¹⁶ and there is only one short sentence about this in the NRMI-2 publication.¹⁰

Predictors of long door to angiography times

An analysis of the NRMI-2 data by Angeja and colleagues¹⁹ described a lot of patient related and hospital related factors being independently associated with longer door to balloon times. These factors are concordant with our findings, especially the finding that door to angiography time increased with increasing pre-hospital delays. This finding may perhaps best be summarised with the notion that if the patient comes late, the doctor does not hurry either. The longer door to balloon times for angioplasty during the night and at low volume hospitals underscore the need for quality control at each hospital.²⁰ The shortened door to angiography times during the last years of the ALKK registry may already be the consequence of the quality control reports of this registry and the increased experience of the centres.

Outcome of long door to angiography times and the paradox of no time dependency of primary angioplasty

The analysis of Cannon and colleagues¹⁰ of the NRMI-2 database is the only adequately powered evaluation showing a clear interaction between door to balloon time and in-hospital mortality: increasing door to balloon time was independently associated with increasing in-hospital mortality. Berger and colleagues²¹ and Juliard and associates²² reported similar results from much smaller patient groups. However, neither the Zwolle data¹⁶ nor our data confirmed these results. Both studies found no association between in-hospital delay and mortality. Are these findings really in contrast to the NRMI-2 data? The main difference between the Zwolle and the ALKK data on the one hand and the NRMI-2 data on the other is the in-hospital delay, which was almost twice as long in the NRMI-2 database as in the two other registries. In the NRMI-2 mortality increased significantly only if the door to balloon time increased over 120 minutes, a delay rarely observed at Zwolle or in the ALKK database. Therefore, the conclusion from the Zwolle and the ALKK data is that, if door to angiography time is < 120 minutes in the vast majority of patients, then in-hospital mortality is not significantly influenced by small time differences within this interval. This conclusion is congruent with the data from NRMI-2.

As a result of this, the door to angiography time analysis strongly supports the hypothesis that primary angioplasty is time dependent, if the analysed time delays are long enough.

When we compared patients with door to angiography times < 120 minutes with the small proportion of patients with door to angiography times ≥ 120 minutes, in-hospital mortality was 8.8% versus 12.2% ($p = 0.118$; after adjustment for confounding parameters, $p = 0.098$). This hypothesis is also supported by the finding that an increasing time delay to the initiation of primary angioplasty compared with the start of thrombolysis is associated with decreasing superiority of primary angioplasty over thrombolysis.^{3, 23}

Is this hypothesis contradicted by the finding in the same study of Cannon and colleagues¹⁰ or other data^{5, 24} that there was no association between mortality and increasing symptom onset to balloon time in primary angioplasty? No, because the symptom onset to balloon time is mainly influenced by pre-hospital delay and only in a small part by door to angiography time. Increasing pre-hospital delays are associated with increasing in-hospital mortality only among patients treated with thrombolysis,^{6–8} not in patients receiving no reperfusion, as shown in the placebo arms of the randomised thrombolysis studies.⁶ The interaction between in-hospital mortality and pre-hospital delay in thrombolysis is mainly caused by the decreasing effectiveness of thrombolysis to achieve TIMI grade 3 flow with increasing pre-hospital delays,^{14, 15} which is not true for primary angioplasty.^{11, 12} This is also supported by a recent paper of Schömig and colleagues,²⁵ who found a treatment dependent influence of time to treatment interval on myocardial salvage in patients with AMI treated with thrombolysis but not in patients treated with primary angioplasty.

Conclusions

In current clinical practice at a variety of hospitals in Germany median door to angiography time is 50 minutes (quartiles of 31–75 minutes). Several patient and hospital related factors are independently associated with a longer door to angiography time. Although we did not find an influence of door to angiography time on in-hospital mortality within these overall short in-hospital delays, we should continue to keep them as short as possible.

Limitations of the study

Several limitations should be considered. This was an observational study with no randomisation to different door to angiography times. We documented door to angiography time but not door to balloon time, so direct comparison of the in-hospital delays with other registries may be difficult. However, needle to balloon time is usually only 10–15 minutes in clinical practice. Since the number of patients with a door to angiography time > 90 minutes was very low, we could not statistically analyse the long time intervals in detail. Therefore, our analysis reflects the consequences only of small differences in door to angiography times as observed in the ALKK data.

Authors' affiliations

R Zahn, U Zeymer, A K Gitt, K Seidl, J Senges, Herzzentrum, Kardiologie, Ludwigshafen, Germany
 A Vogt, Städtisches Klinikum, Kassel, Germany
 M Gottwik, Klinikum Nürnberg Süd, Nuremberg, Germany
 M A Weber, Kreisklinik, Dachau, Germany
 W Niederer, Krankenhaus der Barmherzigen Brüder, Regensburg, Germany
 B Mödl, Städtisches Klinikum, Ingolstadt, Germany
 H-J Engel, Zentralkrankenhaus "Links der Weser", Bremen, Germany
 U Tebbe, Klinikum Lippe Detmold, Detmold, Germany

REFERENCES

- 1 Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. *Lancet* 2003;**361**:13–20.

- 2 **Weaver WD**, Simes RJ, Betriu A, *et al*. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review [published erratum appears in JAMA 1998;279:1876]. *JAMA* 1997;**278**:2093–8.
- 3 **Grines CL**, Patel A, Zijlstra F, *et al*. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. *Am Heart J* 2003;**145**:47–57.
- 4 **Widimsky P**, Budesinsky T, Vorac D, *et al*. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction: final results of the randomized national multicentre trial—PRAGUE-2. *Eur Heart J* 2003;**24**:94–104.
- 5 **Zahn R**, Schiele R, Gitt AK, *et al*. Impact of prehospital delay on mortality in patients with acute myocardial infarction treated with primary angioplasty and intravenous thrombolysis. *Am Heart J* 2001;**142**:105–11.
- 6 **Fibrinolytic Therapy Trialists' (FTT) Collaborative Group**. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients [published erratum appears in Lancet 1994;343:742]. *Lancet* 1994;**343**:311–22.
- 7 **Goldberg RJ**, Mooradd D, Gurwitz J, *et al*. Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction. *Am J Cardiol* 1998;**82**:259–64.
- 8 **Newby LK**, Rutsch WR, Califf RM, *et al*. Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. *J Am Coll Cardiol* 1996;**27**:1646–55.
- 9 **Brodie BR**, Stuckey TD, Wall TC, *et al*. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. *J Am Coll Cardiol* 1998;**32**:1312–9.
- 10 **Cannon CP**, Gibson CM, Lambrew CT, *et al*. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. *JAMA* 2000;**283**:2941–7.
- 11 **Ellis SG**, O'Neill WW, Bates ER, *et al*. Coronary angioplasty as primary therapy for acute myocardial infarction 6 to 48 hours after symptom onset: report of an initial experience. *J Am Coll Cardiol* 1989;**13**:1122–6.
- 12 **Liem AL**, van't Hof AW, Hoortje JC, *et al*. Influence of treatment delay on infarct size and clinical outcome in patients with acute myocardial infarction treated with primary angioplasty. *J Am Coll Cardiol* 1998;**32**:629–33.
- 13 **TIMI Study Group**. The thrombolysis in myocardial infarction (TIMI) trial: phase I findings. *N Engl J Med* 1985;**312**:932–6.
- 14 **Steg PG**, Laperche T, Gilmard JL, *et al*. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective evaluation of reperfusion markers. *J Am Coll Cardiol* 1998;**31**:776–9.
- 15 **Zeymer U**, Tebbe U, Essen R, *et al*. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group. *Am Heart J* 1999;**137**:34–8.
- 16 **De Luca G**, Suryapranata H, Zijlstra F, *et al*. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. *J Am Coll Cardiol* 2003;**42**:991–7.
- 17 **Vogt A**, Bonzel T, Harmjan D, *et al*. PTCA registry of German community hospitals. Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) Study Group. *Eur Heart J* 1997;**18**:1110–4.
- 18 **Vogt A**, Niederer W, Pfaffert C, *et al*. Direct percutaneous transluminal coronary angioplasty in acute myocardial infarction: predictors of short-term outcome and the impact of coronary stenting. Study Group of The Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). *Eur Heart J* 1998;**19**:917–21.
- 19 **Angeja BG**, Gibson CM, Chin R, *et al*. Predictors of door-to-balloon delay in primary angioplasty. *Am J Cardiol* 2002;**89**:1156–61.
- 20 **Caputo RP**, Ho KK, Stoler RC, *et al*. Effect of continuous quality improvement analysis on the delivery of primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. *Am J Cardiol* 1997;**79**:1159–64.
- 21 **Berger PB**, Ellis SG, Holmes DR, *et al*. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in acute coronary syndromes (GUSTO-IIb) trial. *Circulation* 1999;**100**:14–20.
- 22 **Juliard JM**, Feldman LJ, Gilmard JL, *et al*. Relation of mortality of primary angioplasty during acute myocardial infarction to door-to-thrombolysis in myocardial infarction (TIMI) time. *Am J Cardiol* 2003;**91**:1401–5.
- 23 **Nallamothu BK**, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? *Am J Cardiol* 2003;**92**:824–6.
- 24 **Zijlstra F**, Patel A, Jones M, *et al*. Clinical characteristics and outcome of patients with early (<2 h), intermediate (2–4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. *Eur Heart J* 2002;**23**:550–7.
- 25 **Schömig A**, Ndrepepa G, Mehilli J, *et al*. Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis. *Circulation* 2003;**108**:1084–8.

IMAGES IN CARDIOLOGY

doi: 10.1136/hrt.2004.055160

Complete resolution of a large intracardiac mass with medical treatment: an echocardiographic follow up

A 12 year old boy was admitted with supraventricular tachycardia and congestive heart failure. An echocardiogram showed dilatation of all four chambers of the heart with biventricular dysfunction, the left ventricular ejection fraction being 21%. In addition there was a large mass, occupying most of the right atrium, extending to the anterior and lateral wall but free of the interatrial septum and tricuspid valve (panel A). There was no restriction of flow to the right ventricle. Minimal pericardial effusion was present. Haematological, urine, and sputum examinations were normal. Computed tomography and magnetic resonance imaging were performed; however, the nature of the intracardiac mass could not be characterised further. Since the tissue diagnosis could not be made with these investigations, biopsy of the mass was performed using an endomyocardial biop-
tome. The histopathology revealed multiple, well formed necrotising epithelioid cell granulomas along with multinucleated giant cells with focal areas of necrosis, suggestive of a chronic inflammatory disease such as tuberculosis. The patient was treated with a diuretic, digoxin, and amiodarone to control the heart rate and the congestive heart failure. Based on endomyocardial biopsy

Echocardiogram in apical four chamber view showing: (A) a large mass occupying almost whole of right atrium; (B) complete regression of the mass after one year of antitubercular chemotherapy. LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle.

findings and a wide prevalence of tuberculosis in this part of the world, antitubercular chemotherapy was added to his treatment. The patient was closely monitored and successive echocardiograms showed gradual resolution of the right atrial mass in six weeks. Treatment was continued for one year, and the last follow up echocardiogram showed near complete disappearance of the intracardiac mass (panel B). Left ventricular function improved with an ejection fraction of 45%.

N K Goyal
A Saxena
P Chopra

anitasaxena@hotmail.com